Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

Carolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.

A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.

Alexey V. Danilov, MD, PhD, discusses the future of BTK inhibitors in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Anita Kumar, MD, discusses treatment options for patients with mantle cell lymphoma who progress on BTK inhibitors.